📈 Fed's first cut since 2020: Time to buy the dip? See Tech-focused stock picksUnlock AI Picks

VistaGen Therapeutics Inc (VTGN)

NASDAQ
Currency in USD
Disclaimer
3.250
-0.040(-1.22%)
Real-time Data
VTGN Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
3.2203.340
52 wk Range
2.4505.936
Prev. Close
3.29
Open
3.33
Day's Range
3.22-3.34
52 wk Range
2.45-5.936
Volume
35,900
Average Vol. (3m)
105,478
1-Year Change
-44.71%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
VTGN Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
13.000
Upside
+300.000%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

VistaGen Therapeutics Inc Company Profile

Vistagen Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for psychiatric and neurological disorders. The company’s product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. It also develops PH80, a hormone-free, odorless, and tasteless synthetic investigational neuroactive pherine nasal spray for the treatment of menopausal hot flashes related vasomotor symptoms and other women’s health indications; PH15, an investigational neuroactive to treat improve psychomotor or cognitive impairment caused by mental fatigue; PH284, an early-stage investigational neuroactive steroid for the treatment of investigational neuroactive pherine nasal spray for the treatments of loss of appetite associated with chronic disorders, such as cancer or heart disease, as well as cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain to treat disorders. In addition, the company’s clinical-stage pipeline consists of intranasal product candidates from a new class of potential neuroscience therapies comprising pherines. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Compare VTGN to Peers and Sector

Metrics to compare
VTGN
Peers
Sector
Relationship
P/E Ratio
−2.6x−5.0x−0.6x
PEG Ratio
−0.03−0.030.00
Price / Book
0.8x4.8x2.6x
Price / LTM Sales
90.1x7.3x3.1x
Upside (Analyst Target)
264.7%104.1%55.8%
Fair Value Upside
Unlock2.7%7.3%Unlock

People Also Watch

4.420
CAPR
-3.70%
3.980
AFMD
-0.50%
5.200
WPRT
-1.70%
4.345
OSUR
-2.36%

FAQ

What Is the VistaGen Therapeutics (VTGN) Stock Price Today?

The VistaGen Therapeutics stock price today is 3.25

What Stock Exchange Does VistaGen Therapeutics Trade On?

VistaGen Therapeutics is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for VistaGen Therapeutics?

The stock symbol for VistaGen Therapeutics is "VTGN."

What Is the VistaGen Therapeutics Market Cap?

As of today, VistaGen Therapeutics market cap is 89.01M.

What is VistaGen Therapeutics Earnings Per Share?

The VistaGen Therapeutics EPS is -1.32.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.